Advanced Oxygen Therapy

What Advanced Oxygen Therapy does

Advanced Oxygen Therapy Inc. (AOTI) is a publicly traded medical device company (AIM: AOTI, IPO June 2024) that develops and commercializes advanced wound care therapies for chronic non-healing wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. The company is headquartered in Oceanside, California, manufactures at a facility in Galway, Ireland, and operates regional sales/marketing offices in Poole (UK) and St. Petersburg, FL.

AOTI's core technology is the Topical Wound Oxygen (TWO2) multi-modality therapy system, which combines pressurized oxygen delivery (~800 mmHg partial pressure), non-contact cyclical compression (7.5–37.5 mmHg), and fine particulate humidification in a single patient-applied system delivered through two form factors: the Extremity Chamber for leg/foot wounds and the Multi-Patch for wounds elsewhere on the body. The company has expanded its portfolio with the NEXA Negative Pressure Wound Therapy (NPWT) system — a multi-week, multi-patient disposable device with a patented SmartFlow connector and Hydrodynamic Fluid Pump — and supports both platforms with the Engaged Outcomes digital service for remote therapy monitoring, wound imaging, and virtual patient support.

AOTI monetizes primarily through hardware sales of TWO2 and NEXA devices and consumables, reimbursed via a combination of government healthcare payors (US Veterans Administration under a five-year Federal Supply Schedule contract, state Medicaid programs, UK NHS Supply Chain framework) and commercial payors. The company sells through direct enterprise field sales to clinicians, hospital systems, and wound care specialists, and supports patients at home through a dedicated Therapy Support Team that delivers, sets up, and trains on equipment. The company has 11–50 employees and serves over 20,000 patients across the US, UK, Ireland, Germany, the Middle East/Africa/India region, Asia Pacific, and Latin America.

Name

Advanced Oxygen Therapy

Legal name

AOTI Inc.

Website

https://aotinc.net

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Negative Pressure Wound Therapy (NPWT) Systems & Accessories (HLAHALAB)

akta.pro secondary industry

Wound Care & Ulcer Management (HLAKACAN)

Keywords

• Topical oxygen therapy
• Wound care devices
• Negative pressure wound therapy
• Chronic wound healing
• Advanced wound care

Headquarters

HQ city

Oceanside

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of TWO2 therapy systems (Extremity Chamber and Multi-Patch) and NEXA NPWT systems to healthcare providers, patients, and institutional buyers (hospitals, VA, home care settings)
2. Healthcare Reimbursement: Revenue through reimbursement from Veterans Administration, Medicaid programs, NHS, and other government healthcare systems under various contracts and supply agreements

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

Advanced Oxygen Therapy (AOTI) manufactures and sells patented wound care medical devices, primarily the TWO2® Topical Wound Oxygen therapy platform (Extremity Chamber and Multi-Patch delivery systems) and the NEXA™ Negative Pressure Wound Therapy (NPWT) system, designed for treating chronic and acute non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The products are complemented by the Engaged Outcomes digital patient engagement platform that provides remote therapy monitoring and home setup/training support via AOTI's Therapy Support Team.

Product overview

Advanced Oxygen Therapy (AOTI) offers a portfolio of clinically-proven wound healing medical devices centered around two core therapy platforms: the Topical Wound Oxygen (TWO2®) multi-modality therapy system and the NEXA™ Negative Pressure Wound Therapy (NPWT) system. The TWO2 platform delivers pressurized oxygen, non-contact cyclical compression, and humidification directly to chronic and acute wounds through two delivery methods: the Extremity Chamber (for wounds on legs/feet) and the Multi-Patch (for wounds across the body). The NEXA NPWT system is a disposable negative pressure wound therapy device. Both platforms are supported by the Engaged Outcomes digital service for remote patient monitoring and therapy support. All products are FDA cleared.

Differentiator

Problem solved

Functional benefit

Brands

• TWO2: Topical Wound Oxygen therapy system for chronic wound healing, including the Extremity Chamber and Multi-Patch products.
• NEXA
• Engaged Outcomes

Products and services

• TWO2® Topical Wound Oxygen Therapy Platform A multi-modality patient-administered wound therapy platform that delivers pressurized oxygen, non-contact cyclical compression, and humidification directly to chronic and acute wounds. Includes the Extremity Chamber and Multi-Patch delivery systems and is intended for clinicians treating diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
• TWO2® Extremity Chamber A chamber-based system that delivers cyclical pressurized topical oxygen therapy to wounds on the lower extremities. Available in medium and large sizes to accommodate wounds from the lower two-thirds of the leg up to the knee. Used with conventional compression dressings, UNNA boots, or total contact casts by wound care clinicians for DFU and VLU treatment.
• TWO2® Multi-Patch A flexible, patch-based system that can be sized and customized to accommodate a wide variety of ulcer sizes or shapes and applied almost anywhere on the body. Delivers a 5-fold increase in pO2 to amplify local immune response, stimulate angiogenesis, and enhance collagen synthesis. Not available in the EU region.
• NEXA™ NPWT System A multi-week, multi-patient, disposable Negative Pressure Wound Therapy (NPWT) system designed for use in home, acute, and extended care settings. Features single-button operation, approximately 10-hour battery life, and a 56-day operational lifespan. Includes patented Hydrodynamic Fluid Pump and SmartFlow™ Connector innovations for multi-patient use and seamless hospital-to-home transition. FDA 510(k) cleared July 2024 for home care use.
• Engaged Outcomes (Eyes on the Wound) A digital patient engagement platform that provides remote therapy monitoring, virtual therapy support, and wound imaging services for patients receiving TWO2 and NEXA therapy at home. Includes at-home therapy patient-applied daily with support from the AOTI Therapy Support Team for equipment set-up, training, and ongoing patient engagement.

Quantifiable outcome

• 88% reduction in hospitalizations for DFU patients treated with TWO2 therapy
• +7 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• National Health Service (NHS)coreChannel Partner/ Reseller/ Distributor · 22 April 2025TWO2 therapy included in NHS supply chain framework agreement for 2025, enabling distribution through UK healthcare system to NHS patients.
• Veterans Administration (VA)coreChannel Partner/ Reseller/ Distributor · 12 December 2024AOTI awarded five-year extension to Veterans Administration contract (contract number: 36F79719D0186) covering TWO2 therapy reimbursement for Veterans. VA is the largest Integrated Health Network in the USA serving 23 million Veterans.
• Amputation Prevention Alliance (APA)coreStrategic or Co-development PartnerPartnership focused on preventing unnecessary amputations for diabetic patients through enhancing education and healthcare accessibility. AOTI is a Founding Partner. Through this partnership, the companies are educating decision-makers and state agencies about the science and successes of Topical Oxygen Therapy.
• Society for Vascular Surgery (SVS)coreStrategic or Co-development PartnerPartnership focused on transforming vascular health through research, innovation and comprehensive care. AOTI participates in Society for Vascular Surgery Annual Meeting.
• American Limb Preservation Society (ALPS)coreStrategic or Co-development PartnerPartnership dedicated to eliminating preventable amputations over the next generation through advancements in science and clinical care.
• American Diabetes Association (ADA)coreStrategic or Co-development PartnerADA awarded Topical Oxygen Therapy an A-grade adjunctive treatment recommendation for diabetic foot ulcers. Partnership includes Amputation Prevention Alliance collaboration and participation in ADA Scientific Sessions.
• American Academy of Home Care Medicine (AAHCM)secondaryStrategic or Co-development PartnerPartnership focused on delivering interdisciplinary, high-value health care in the home for all people in need by promoting the art, science, and practice of home care medicine.
• American Venous Forum (AVF)secondaryStrategic or Co-development PartnerPartnership focused on improving the care of patients with venous and lymphatic disease through research and clinical advancement.

Scale indicators10 records

Recent moves1 record

Expansion highlights6 records

Direct peers

• Smith+Nephew: Global medical device company with a substantial Advanced Wound Management portfolio including the PICO single-use NPWT system. Directly comparable to AOTI in NPWT and chronic wound care for hospital, community, and home settings.
• Solventum (formerly 3M Health Care / KCI): Inventor of V.A.C. negative pressure wound therapy and a leading global wound care franchise. Most directly comparable NPWT competitor to AOTI's NEXA system, with broad hospital and home-care channel coverage.
• Mölnlycke Health Care: Swedish wound care and surgical solutions company offering Mepilex dressings and Avance NPWT systems. Competes head-to-head with AOTI in chronic wound management across hospital and home-care channels.
• ConvaTec Group: Publicly-listed wound care, ostomy, and continence device company with an advanced wound care portfolio including foam dressings and NPWT products. Comparable to AOTI's TWO2/NEXA positioning for chronic wound patients.

Broad incumbents

• Coloplast: Danish medical device company with a significant wound care business (Biatain dressings) alongside ostomy and continence. Overlaps with AOTI in advanced wound care for chronic wounds across similar customer segments.
• Integra LifeSciences: Publicly-listed medical technology company with a dedicated Wound Care and Tissue Reconstruction portfolio including dermal matrices and skin grafts. Targets the same chronic and complex wound market as AOTI's TWO2 therapy.
• Organogenesis Holdings: Publicly-traded regenerative medicine company focused on advanced wound care and surgical biologics (Apligraf, Dermagraft). Comparable to AOTI in serving chronic wound patients (DFU, VLU) with clinically differentiated products.

Emerging players

• MiMedx Group: Publicly-traded company commercializing placental tissue allografts (EpiFix, AmnioFix) for chronic wound care and surgical recovery. A niche/emerging competitor targeting similar DFU/VLU patient populations as AOTI.

Others

• Cardinal Health: Major US medical products distributor that supplies wound care products, NPWT devices, and dressings to hospitals, home health agencies, and DME providers — overlapping with AOTI's distribution channel and customer base.

Regional players

• Paul Hartmann AG: German medical and wound care company with a strong European footprint (HydroTherapy, RespoSorb, Atrauman). Operates in similar wound care categories as AOTI, with primary geographic overlap in Germany and broader EU markets.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@aotinc
• Facebookfacebook.com/advancedoxygentherapyinc
• LinkedInlinkedin.com/company/322686
• Xx.com/aotiltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Oxygen Therapy